Chembio Diagnostics' DPP COVID-19 Antigen Test Approved In South Africa

  • South Africa Health Products Regulatory Authority (SAHPRA) has approved Chembio Diagnostics Inc's CEMI DPP SARS-CoV-2 Antigen test for use at the point of care.
  • The DPP SARS-CoV-2 Antigen test has been designed to detect SARS-CoV-2 antigens in only 20 minutes. 
  • The antigen test uses a minimally invasive nasal swab and is designed to be read visually or with a DPP Micro Reader 2 optical analyzer. 
  • The DPP SARS-CoV-2 Antigen test and the IgM/IgG Antibody test are authorized for import and distribution in South Africa by Chembio's distributor, Patient Focus Africa. 
  • Related: Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test.
  • Price Action: CEMI shares are up 15% at $2.30 during the market session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!